Citation tools
"JNJ-26070109 [(R)4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability." Journal of Pharmacology and Experimental Therapeutics
338.1
(2011):
328-336.
Web. 19 April. 2024.